


<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>  <div style="text-align: center;">   <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> </div>  <b>(37 CFR 1.98(b))</b>	<b>ATTY. DOCKET NO.</b>  00-149	<b>SER. NO.</b>  09/816700
	<b>APPLICANT</b>  WONG et al.	
	<b>FILING DATE</b>  March 16, 2001	<b>GROUP</b>  1648 1642

**RECEIVED**

JUL 15 2002

TECH CENTER 1600/2000

**U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
_____						
_____						
_____						
_____						
_____						
_____						
_____						

**RECEIVED**

JUL 15 2002

TECH CENTER 1600/2000

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
KAC		WO 01/62930 A1	8/30/01	WO		
_____						
_____						
_____						
_____						
_____						
_____						

**OTHER DOCUMENTS**


(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
KAC		Ellerby, H. M. et al.; Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides; Nature Medicine, Vol. 5, No. 9, pp. 1032-1038; 1999.
_____		
_____		
_____		

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<i>Karen A. Gamella</i>	3/31/05

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE   INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))	ATTY. DOCKET NO.  00-149	SER. NO.  09/810,700	TECH CENTER 1600/2900 AUG 27 2001
	APPLICANT  Wong et al.		
	FILING DATE  March 16, 2001	GROUP  unknown	

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
KAC		6,051,230	Apr. 18, 2000	Thorpe et al.		Jun. 1, 1995
KAC		5,965,132	Oct. 12, 1999	Thorpe et al.	424/149	Dec. 5, 1994
KAC		5,855,866	Jan. 5, 1999	Thorpe et al.	424/1.49	Mar. 2, 1994
KAC		6,261,535	Jul. 17, 2001	Thorpe et al.	424/1.49	Dec. 8, 1998

## OTHER DOCUMENTS


(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
KAC		Ghose et al., Preparation of antibody-linked cytotoxic agents. Methods Enzymol. 93: 280-333, 1983.
KAC		Ghose et al., The design of cytotoxic-agent-antibody conjugates. Crit. Rev. Ther. Drug. Carrier Syst. 3(4):263-359. 1987.
KAC		Pierschbacher M.D. and Ruoslahti E. The cell attachment activity of fibronectin can be duplicated by small fragments of the molecule. Nature 1984; 309:30.
KAC		Koivunen E, Gay D, Ruoslahti E. Selection of peptides binding to the $\alpha_5\beta_1$ integrin from phage display library. J Biol Chem 1993; 268: 20205.
KAC		Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the $\alpha_5\beta_1$ integrin from a phage display library. J Cell Biol 1994; 124:373.
KAC		Healy JM, Murayama O, Maeda T, et al. Peptide ligands for integrin $\alpha_5\beta_3$ selected from random phage display libraries. Biochemistry 1995; 34:3948.
KAC		Pasqualini R, Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380:364.
KAC		Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102:430.
KAC		Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Ca Res 2000; 60:722.
KAC		Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315.
KAC		Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249:386.
KAC		Clackson T, Wells JA. In vitro selection from protein and peptide libraries. Trends Biothechnol 1994; 12:173.

RECEIVED

AUG 27 2001


TECH CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00-149	SER. NO. 09/810,700
		APPLICANT Wong et al.	
		FILING DATE March 16, 2001	GROUP unknown

(37 CFR 1.98(b))

Examiner Initial	Cite No. <sup>1</sup>	
KAC		Colas P, Cohen B, Jessen T, et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. <i>Nature</i> 1996; 380:548.
KAC		Lu Z, Murray KS, van Cleave V, et al. Expression of thioredoxin random peptide libraries on <i>Escherichia coli</i> ( <i>E. coli</i> ) cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. <i>Bio/Technology (NU)</i> 1995; 13:366.
KAC		Baatout S. Endothelial differentiation using Matrigel ( <i>Review</i> ). <i>Anticancer Res</i> 1997; 17:451.
KAC		Zhu D, Pauli BU. Generation of monoclonal antibodies directed against organ-specific endothelial cell surface determinants. <i>J Histochem Cytochem</i> 1991; 39:1137.
KAC		Pierschbacher MD, Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. <i>Proc Natl Acad Sci USA</i> 1984; 81:5985.
KAC		Yamada KM, Kennedy DW. Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. <i>J Cell Biol</i> 1984; 99:29.
KAC		Gartner TK, Bennett JS. The tetrapeptide analog of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. <i>J Biol Chem</i> 1985; 260:11891.
KAC		Plow EF, Pierschbacher MD, Ruoslahti E, et al. The effect of Arg-Gly-Asp containing peptides on fibrinogen and von Willebrand factor binding to platelets. <i>Proc Natl Acad Sci USA</i> 1985; 82:8057.
KAC		Brown CK, Modzelewski RA, Johnson CS, and Wong MKK. A novel approach for the identification of unique tumor vasculature binding peptides using an <i>E. coli</i> peptide display library. <i>Ann. Of Surg. Onc.</i> 2000; 7(10): 743-749.
KAC		Suzuki S, Oldberg A, Hayman EG, et al. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. <i>EMBO J</i> 1985; 4:2519.
KAC		Gardner JM, Hynes RO. Interaction of fibronectin with its receptor on platelets. <i>Cell</i> 1985; 42:439.
KAC		Ito Y, Iwamoto Y, Tanaka K, et al. A quantitative assay using basement membrane extracts to study tumor angiogenesis <i>in vivo</i> . <i>Int J Cancer</i> 1996; 67:148.

RECEIVED

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>   <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY. DOCKET NO.</b> 00-149	<b>SER. NO.</b> 09/810,700
	<b>APPLICANT</b> Wong et al.	
	<b>FILING DATE</b> March 16, 2001	<b>GROUP</b> unknown
	<b>TECH CENTER</b> 1600/2900	

AUG 2 7 2001

Examiner Initial	Cite No.	
KAC		Modzelewski RA, Davies P, Watkins SC, Auerback R, Chang M-J, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Ca Res.1994, 54:336-339.

EXAMINER	DATE CONSIDERED
<i>Karen G. Gamella</i>	3/31/05

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.